SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-22-013535 to biote Corp. (BTMD) (CIK 0001819253) (BTMD)

biote Corp. (BTMD) (CIK 0001819253)
Date: Dec. 15, 2022 · CIK: 0001819253 · Accession: 0000000000-22-013535

Regulatory Compliance Financial Reporting Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-268748

Date
December 15, 2022
Author
Terry Weber
Form
UPLOAD
Company
biote Corp. (BTMD) (CIK 0001819253)

Letter

United States securities and exchange commission logo December 15, 2022 Terry Weber Chief Executive Officer biote Corp. 1875 W. Walnut Hill Ln #100 Irving, TX 75038 Re:biote Corp. Registration Statement on Form S-1 Filed December 12, 2022 File No. 333-268748 Dear Terry Weber : This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text
United States securities and exchange commission logo
December 15, 2022
Terry Weber
Chief Executive Officer
biote Corp.
1875 W. Walnut Hill Ln #100
Irving, TX 75038
Re:biote Corp.
Registration Statement on Form S-1
Filed December 12, 2022
File No. 333-268748
Dear Terry Weber :
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences